SAN DIEGO & DUBLIN--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Endo International Plc (NYSE: ENDP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 8, 2017 and June 10, 2020. Endo manufactures and sells generic and branded pharmaceuticals in the U.S. and internally, including both generic and branded opioid products.
If you suffered a loss as a result of Endo's misconduct, click here.
Endo International Plc (ENDP) Under Investigation by New York Department of Financial Services (DFS)
According to the complaint, on June 10, 2020, the New York Department of Financial Services ("DFS") announced that it had filed charges against the Company and its subsidiaries in connection with the opioid crisis. DFS claims that Endo "[k]nowingly furthered a false narrative to legitimize opioids as appropriate for broad treatment of pain by downplaying their long-known addictive nature and risks”; “[m]isrepresented the safety and efficacy of opioids, without legitimate scientific substantiation”; and “[d]eployed a large sales force to target healthcare providers directly with these misrepresentations.” On this news, Endo's stock price fell over 14% to close at $3.85. The stock has yet to recover.
Endo International Plc (ENDP) Shareholders Have Legal Options
Want to be notified if a class action against Endo settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.